Abstract
Redox status is closely associated with the development and progression of cancer, which can be modulated by long non-coding RNA (lncRNA). A series of previous studies have demonstrated that redox regulation can be treated as a potential treatment option for cancer. However, the redox-related lncRNA predictive signature of bladder cancer (BCa) still remains unknown. The purpose of our study is to construct a redox-related lncRNA signature for better prediction of BCa patients’ prognosis. We downloaded transcriptome and clinical data from the Cancer Genome Atlas (TCGA) database. The prognostic redox-related lncRNAs were identified by univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression analysis and two risk groups were established. A comprehensive analysis corresponding to clinical features between high-risk and low-risk groups was conducted. Eight redox-lncRNAs (AC018653.3, AC090229.1, AL357033.4, AL662844.4, AP003352.1, LINC00649, LINC01138, MAFG-DT) were selected and constructed the risk model. The overall survival (OS) in high-risk group was worse than that in low-risk group (p < 0.001). The redox-related lncRNA signature has a better predictive accuracy than clinicopathological characteristics. GSEA analysis showed the MAPK signaling pathway and WNT signaling pathway were enriched in the high-risk group. Compared with the low-risk group, the patients in high-risk group were more sensitive to cisplatin, docetaxel, and paclitaxel. Furthermore, IGF2BP2, a potential target gene of MAFG-DT, was overexpressed in tumor tissues and was correlated with OS. Our study proved that the predictive signature constructed by eight redox-related lncRNAs can independently and accurately predict the prognosis of BCa patients.